Zydus Lifesciences Ltd 2021 AR2
The report highlights Cadila Healthcare Limited's (Zydus) operations and financial performance for the fiscal year 2020-2021, emphasizing its leadership in the fight against COVID-19. The company developed ZyCoV-D, the world's first Plasmid DNA vaccine, and launched several therapeutics like Virafin and Remdac to treat patients. Financially, consolidated revenue from operations grew by 6% to ₹151 billion, and net profit increased by 81% to ₹21.3 billion. The company also reduced its net debt by ₹32 billion and expanded its CSR initiatives, particularly through the Zydus Medical College and Hospital in Dahod.
Company: Zydus Lifesciences Ltd
Sector: Health Care
Country: India
Year: 2021
Type: AR2
Pages: 241
Zydus Lifesciences Ltd
Annual Report
The report highlights Cadila Healthcare Limited's (Zydus) operations and financial performance for the fiscal year 2020-2021, emphasizing its leadership in the fight against COVID-19. The company developed ZyCoV-D, the world's first Plasmid DNA vaccine, and launched several therapeutics like Virafin and Remdac to treat patients. Financially, consolidated revenue from operations grew by 6% to ₹151 billion, and net profit increased by 81% to ₹21.3 billion. The company also reduced its net debt by ₹32 billion and expanded its CSR initiatives, particularly through the Zydus Medical College and Hospital in Dahod.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees